N4 PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.775 GBX | -6.06% |
|
-8.82% | -8.82% |
| Apr. 25 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
| Apr. 23 | N4 Pharma loss widens but "great optimism" remains | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
N4 Pharma Plc is a United Kingdom-based specialist pharmaceutical company. The Company is focused on developing a silica nanoparticle delivery system to improve the cellular delivery of cancer treatments and vaccines. The Company is engaged in the development and commercialization of medicines through its delivery system, Nuvec. Nuvec is a silica nanoparticle technology with a patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical Phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. The Companyâs wholly owned subsidiaries include N4 Pharma UK Limited.
Sector
Pharmaceuticals
Calendar
2024-09-17
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.82% | 2.59M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ONZ Stock
- News N4 Pharma Plc
- N4 Pharma Shows Increased Transduction Efficacy for Silica Nanoparticle
